Due to the seemingly insatiable appetites of companies like Teva (NYSE:TEVA), Mylan (Nasdaq:MYL) and Watson (NYSE:WPI), there aren't nearly as many independent publicly-traded generic drug companies as there used to be. While scarcity value alone is not a good argument for considering Hi-Tech Pharmacal (Nasdaq:HITK), this company's focus on higher-barrier products and over-the-counter (OTC) cold and cough business, coupled with little sell-side support, could make it a potential hidden gem at some point.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

Fiscal Fourth Quarter Results Disappointing, but not Disastrous
Hi-Tech's fiscal fourth quarter results don't exactly establish the case that this is a must-watch stock for investors seeking out small-cap growth names.

Revenue was up 7% (and a little stronger than expected), with 10% growth in the generics business. Sales of the key drug fluticasone (a generic form of Glaxo's (NYSE:GSK) Flonase) rose 6% - again, a little better than expected, but not exactly strong. The entry of Wockhardt has taken some share away from Hi-Tech Pharmacal, but the company seems to be largely holding its own.

Hi-Tech's other line items, OTC products ((reported as Health Care Products (HCP)) and branded drugs ("ECR Pharmaceuticals") had radically different results. HCP revenue jumped 59% despite a weak cold/flu season, largely on the strength of mergers and acquisitions. ECR saw revenue drop 44% on a product line discontinuation. Investors should note, though, that when combined these two units are less than 15% of revenue.

Where Hi-Tech really disappointed me was on the gross margin line. Gross margin dropped about three points due to weaker fluticasone pricing and the drop in branded drug sales. The company continued to grow its SG&A and R&D efforts, though, and that helped push operating income down 28%.

SEE: Understanding The Income Statement

Building Around Core Competencies
Smart small companies focus on doing a small number of things better than their larger rivals, and Hi-Tech seems to be following that plan. It has focused largely on liquid and semi-solid dosage forms, giving it a leveragable product or market niche. At the same time, the company looks to take on products with higher barriers to entry (often harder to formulate or manufacture). This is a sound strategy, as it can allow the company to realize higher prices and margins than would otherwise be the case in "mass market" generics.

The company is also being prudently aggressive about growing its business. There are 14 products awaiting approval from the FDA, and another 20 in development. The largest among them (in sales potential, at least) is a generic form of Asacol - a bowel-specific anti-inflammatory drug that Warner Chilcott (Nasdaq:WCRX) markets for IBD, ulcerative colitis and Crohn's. Hi-Tech is partnered with Par Pharmaceuticals (NYSE:PRX) for this drug and it could be a significant contributor to earnings, though approval and launch timing is still uncertain and Warner Chilcott has been trying to migrate patients to different, still patent-protected forms of the drug.

Time to Be More Aggressive?
With a clean balance sheet, I believe it's fair to ask if Hi-Tech management shouldn't be a little more aggressive. In particular, I wonder if the company could use that balance sheet to acquire smaller generics companies and/or additional branded drugs. There are more than a few branded drugs in the hands of Big Pharma that are profitable, but don't produce enough revenue to "move the needle;" if Hi-Tech could identify a few that are non-core to the current owner, but consistent with Hi-Tech's position in markets like cold/allergy/cough, it could be a "win win" for both parties.

SEE: Earning Forecasts: A Primer

The Bottom Line
This is perhaps not the easiest time to be bullish about the generic drug space. With fewer high-profile branded drug patent expirations on the horizon, investors seem to have soured on the sector's prospects for continued above-average revenue and margin expansion - even though the upholding of the Affordable Care Act would seem to be good news for generic prescription trends.

Likewise, Hi-Tech isn't a slam-dunk growth story. The company is hugely reliant on fluticasone for its profits and rivals like Teva could still enter the market. What's more, management doesn't often target the sort of home run prospects that tend to get sell-side analysts and buy-side managers giddy. All of that said, the stock looks too cheap today and I think investors may want to take a closer look at this name.

At the time of writing, Stephen D. Simpson did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    Starbucks: Profiting One Cup at a Time (SBUX)

    Starbucks is everywhere. But is it a worthwhile business? Ask the shareholders who've made it one of the world's most successful companies.
  2. Stock Analysis

    How Medtronic Makes Money (MDT)

    Here's the story of an American medical device firm that covers almost every segment in medicine and recently moved to Ireland to pay less in taxes.
  3. Investing News

    Latest Labor Numbers: Good News for the Market?

    Some economic numbers are indicating that the labor market is outperforming the stock market. Should investors be bullish?
  4. Investing News

    Stocks with Big Dividend Yields: 'It's a Trap!'

    Should you seek high yielding-dividend stocks in the current investment environment?
  5. Investing News

    Should You Be Betting with Buffett Right Now?

    Following Warren Buffett's stock picks has historically been a good strategy. Is considering his biggest holdings in 2016 a good idea?
  6. Products and Investments

    Cash vs. Stocks: How to Decide Which is Best

    Is it better to keep your money in cash or is a down market a good time to buy stocks at a lower cost?
  7. Investing News

    Who Does Cheap Oil Benefit? See This Stock (DG)

    Cheap oil won't benefit most companies, but this retailer might buck that trend.
  8. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  9. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  10. Investing News

    The UAE: An Emerging Economy for Investors

    The learning from UAE on how it succeeded with timely diversification when the BRICS nations and the neighboring oil-rich economies faced challenges.
  1. When does a growth stock turn into a value opportunity?

    A growth stock turns into a value opportunity when it trades at a reasonable multiple of the company's earnings per share ... Read Full Answer >>
  2. What is the formula for calculating EBITDA?

    When analyzing financial fitness, corporate accountants and investors alike closely examine a company's financial statements ... Read Full Answer >>
  3. How do I calculate the P/E ratio of a company?

    The price-earnings ratio (P/E ratio) is a valuation measure that compares the level of stock prices to the level of corporate ... Read Full Answer >>
  4. How do you calculate return on equity (ROE)?

    Return on equity (ROE) is a ratio that provides investors insight into how efficiently a company (or more specifically, its ... Read Full Answer >>
  5. How do you calculate working capital?

    Working capital represents the difference between a firm’s current assets and current liabilities. The challenge can be determining ... Read Full Answer >>
  6. What is the formula for calculating the current ratio?

    The current ratio is a financial ratio that investors and analysts use to examine the liquidity of a company and its ability ... Read Full Answer >>
Trading Center